Streetbeat News

Revenues

BLFS

BioLife Solutions has reaffirmed its 2024 revenue guidance, projecting $95.5 million to $100.0 million. This forecast includes contributions from its Cell Processing and Biostorage Services platforms, incorporating the ThawSTAR product line but excluding the freezer product line (GCI and CBS). The Cell Processing platform is expected to generate $66.0 million to $68.5 million, marking up to a 4% increase from 2023, or 17% to 22% based on the second half of 2023's revenue run rate. The Biostorage Services platform, now including ThawSTAR, anticipates $29.5 million to $31.5 million in revenue, a 5% to 12% increase from 2023, or 10% to 16% without ThawSTAR.

Portfolio Pulse from Benzinga Newsdesk

May 09, 2024 | 8:10 pm

NTRA

Natera projects its total revenue for 2024 to be between $1.42 billion and $1.45 billion, surpassing the estimated $1.34 billion.

Portfolio Pulse from Benzinga Newsdesk

May 09, 2024 | 8:10 pm

YELP

Yelp reported Q1 sales of $333.00M, missing the consensus estimate of $333.44M by 0.13%, marking a 6.58% increase from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

May 09, 2024 | 8:08 pm

PNTG

Over the last three months, Pennant Gr (NASDAQ:PNTG) received diverse analyst evaluations, with recent updates showing a positive trend in price target adjustments. Four analysts have provided ratings, with a shift towards a more bullish outlook in the last 30 days. The average 12-month price target has been raised to $23.00, indicating a 25.48% increase from the previous target of $18.33. Analysts from RBC Capital, Stephens & Co., Oppenheimer, and Truist Securities have adjusted their ratings and price targets, reflecting optimism about Pennant Gr's market performance. The company, operating in healthcare services, has shown strong financial indicators such as a 17.08% revenue growth rate, a net margin of 2.98%, and an ROE of 3.16%, despite a high debt-to-equity ratio of 2.35.

Portfolio Pulse from Benzinga Insights

May 09, 2024 | 8:01 pm

PSNL

Personalis (NASDAQ:PSNL) received varied analyst ratings, with a consensus pointing towards a bullish outlook. The average 12-month price target is $3.62, marking a significant increase from the previous $2.30. The company's financial performance shows a positive revenue trend with a growth rate of 17.66% as of December 31, 2023, and a notable net margin of -135.12%. Despite a below-average ROA, Personalis exhibits strong profitability and effective cost management, with a debt-to-equity ratio of 0.37.

Portfolio Pulse from Benzinga Insights

May 09, 2024 | 8:00 pm

ELAN

Elanco Animal Health (NYSE:ELAN) has received mixed analyst ratings over the past quarter, with a recent shift towards more positive evaluations. Analysts from Barclays, Piper Sandler, Goldman Sachs, and Morgan Stanley have adjusted their price targets upwards, reflecting an optimistic outlook on the company's future performance. The average 12-month price target is now $18.2, up 17.42% from the previous $15.50, indicating a bullish sentiment. Despite this, Elanco faces challenges in revenue growth, net margin, ROE, and ROA, lagging behind industry averages.

Portfolio Pulse from Benzinga Insights

May 09, 2024 | 8:00 pm

FLYW

Analyst ratings for Flywire (NASDAQ:FLYW) show a mix of bullish to bearish sentiments, with recent actions including both raises and lowers in ratings and price targets. The average 12-month price target is now $32.2, down from $33.00. Flywire's financial performance highlights a significant revenue growth rate of 37.63% as of December 31, 2023, but challenges in profitability and efficiency metrics like net margin, ROE, and ROA are noted.

Portfolio Pulse from Benzinga Insights

May 09, 2024 | 8:00 pm

TARS

Analyst ratings for Tarsus Pharmaceuticals (NASDAQ:TARS) have shown a positive shift with an average 12-month price target of $50.17, up 18.97% from the previous target. Ratings have evolved over the past three months, with recent updates from analysts at Oppenheimer, Jefferies, Goldman Sachs, HC Wainwright & Co., and Barclays, all raising their price targets. Tarsus Pharmaceuticals, a commercial-stage biopharmaceutical company, has seen a revenue growth rate of 30.76% as of December 31, 2023, but struggles with a net margin of -320.45% and below-average ROE and ROA.

Portfolio Pulse from Benzinga Insights

May 09, 2024 | 8:00 pm

HPK

SU

TNK

Shares of companies in the Oil and Gas sector, including HPK, SU, and TNK, are trading higher due to an increase in crude oil prices and a year-over-year rise in China's April crude oil imports.

Portfolio Pulse from Benzinga Newsdesk

May 09, 2024 | 7:52 pm

AAPL

CMCSA

DIS

NFLX

ROKU

SIRI

SPOT

A new survey reveals that wealthier Americans are more likely to subscribe to multiple streaming platforms, with Netflix, Disney+, and Hulu leading in popularity across different income levels. Netflix Inc (NFLX) and The Walt Disney Company (DIS) reported significant subscriber growth, with other companies like Comcast Corporation (CMCSA), Roku Inc (ROKU), Spotify Technology (SPOT), Sirius XM Holdings (SIRI), and Apple Inc (AAPL) also seeing varied levels of usage among income groups. The survey highlighted the disparities in platform usage across income levels and the trend of media companies offering bundles to address the challenge of platform proliferation.

Portfolio Pulse from Chris Katje

May 09, 2024 | 7:51 pm